NICE Decision on Alzheimer Drugs Due April 2006
Posted on: Friday, 20 January 2006, 06:00 CST
By Anonymous
The NICE Alzheimer's drugs appraisal committee meets again next week to consider evidence on the effectiveness of drugs for the treatment of subgroups of patients with Alzheimer's disease.
The committee will consider data from pharmaceutical companies on the effectiveness of cholinesterase inhibitors.
The final draft of its review of donepezil, rivastigmine. galantamine and memantine for the treatment of Alzheimer's disease is not expected until April 2006.
The review was meant to be completed by October, but was delayed because of an outcry at proposals that cholinesterase inhibitors should not be given first line to patients with newly diagnosed Alzheimer's on the NHS.
Original NICE guidance still stands. It recommended that donepezil, rivastigmine and galantamine should be made available on the NHS as one part of the management of some patients with mild and moderate Alzheimer's disease.
Copyright Haymarket Business Publications Ltd. Dec 16, 2005
Source: GP
Related Articles
- Hypertension, Inflammation Common In Offspring Of Alzheimer's Disease Patients
- EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer's Disease Patient
- Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients.
- The Lancet Neurology Publishes Clinical Results of PBT2 in Alzheimer's Disease Patients
- Medivation's Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimer's Disease Patients Over One Year
- Medivation's Dimebon(TM) Significantly Improved Daily Function in Alzheimer's Disease Patients, Resulting in Reduced Need for Caregiver Assistance
- Prana Announces Completion of Phase IIa Trial of PBT2 in Alzheimer's Disease Patients
- Prana Provides Update on Phase IIa PBT2 Trial in Alzheimer's Disease Patients
- PBT2 Phase IIa Clinical Trial in Alzheimer's Disease Patients
- Predix Pharmaceuticals Announces Positive Findings From First Clinical Trial in Alzheimer's Disease Patients
 |
 |
User Comments (0)
RSS Feeds